Company Profile
Pharvaris Stock Price, News & Catalysts
- Ticker:
- PHVS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Netherlands
Stock performance
38.00 USD (+1.20%)
Close
Last updated: September 17, 2026
2.03B USD
Market cap
Why the stock is moving
As of Sep 17, 2026, PHVS closed up 1.20% at $38.00. No new same-company headline was identified in the current news window.
Company overview
Oral Bradykinin Therapeutics
Pharvaris develops deucrictibant, an oral small-molecule bradykinin B2 receptor antagonist for hereditary and acquired angioedema.
On-Demand Formulation
Immediate-release deucrictibant is intended to treat acute hereditary angioedema attacks with an oral alternative to injectable therapies.
Prophylactic Formulation
Extended-release deucrictibant is designed for prevention of attacks, allowing the same molecule to address both acute and chronic treatment.
Future catalysts
- An NDA submission for immediate-release deucrictibant in on-demand hereditary angioedema treatment is planned for the first half of 2026.
- Topline data from the pivotal Phase 3 CHAPTER-3 prophylaxis study are expected in the third quarter of 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Pharvaris (PHVS)?
Pharvaris (PHVS) most recently closed at 38.00 USD, a +1.20% move versus the previous session.
What is the market cap of Pharvaris (PHVS)?
Pharvaris currently has a market capitalization of 2.03B USD on BioPharmSignal.
What does Pharvaris do?
Oral Bradykinin Therapeutics Pharvaris develops deucrictibant, an oral small-molecule bradykinin B2 receptor antagonist for hereditary and acquired angioedema. On-Demand Formulation Immediate-release deucrictibant is intended to treat acute hereditary angioedema attacks with an oral alternative to injectable therapies. Prophylactic...
On which exchange is PHVS stock listed?
Pharvaris (PHVS) is associated with NASDAQ, Netherlands, Biopharma.
What is CHAPTER-3?
Topline data from the pivotal Phase 3 CHAPTER-3 prophylaxis study are expected in the third quarter of 2026.
Which conditions is Pharvaris targeting with CHAPTER-3?
Topline data from the pivotal Phase 3 CHAPTER-3 prophylaxis study are expected in the third quarter of 2026.
How does Pharvaris describe recent progress with CHAPTER-3?
Topline data from the pivotal Phase 3 CHAPTER-3 prophylaxis study are expected in the third quarter of 2026.
What is Oral?
Oral Bradykinin Therapeutics Pharvaris develops deucrictibant, an oral small-molecule bradykinin B2 receptor antagonist for hereditary and acquired angioedema.